Msc- and exosome-based immunotherapy
AssigneeExostem Biotec Ltd.
InventorsAharon BRODIE, Chaya BRODIE
Life of this patent
Estimating the term…
Abstract
Compositions comprising at least one of miR that down regulates PD-L1/PD-1, MSCs expressing same, or exosomes from those MSCs are provided. Methods of decreasing PD-L1 expression, PD-1 expression or both and treating PD-L1 positive cancers using same are also provided.
Claims58
A method of decreasing Programmed Death Ligand 1 (PD-L1) expression, PD-1 expression, or both, in a cell, the method comprising contacting said cell with a chorionic placenta (CH) mesenchymal stem cell (MSC), extracellular vesicle from said CH-MSC or both, optionally wherein said cell is a cancer cell.
(canceled)
(canceled)
(canceled)
A method of decreasing proliferation of a cancer cell, the method comprising contacting said cancer cell with a chorionic placenta (CH)MSC, extracellular vesicle from said MSC or both.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising at least one of:
- a. a chorionic placenta (CH) MSC expressing at least one exogenous miR selected from miR-124, miR-29c miR-383 miR-373, miR-548, miR-559, miR-1304, miR-519, miR-377, miR-378, miR-200, miR-424, miR-570, and miR-34;
- b. extracellular vesicles derived from (a);
- c. a combination thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.